The understanding of polypoidal choroidal vasculopathy has evolved rapidly in the past three decades. The hallmark of the disease is the presence of typical hyperfluorescent nodules in the early phase ...

Please provide your email address to receive an email when new articles are posted on . An accurate diagnosis and the correct identification of the polypoidal choroidal vasculopathy subtype of wet ...

This is a retrospective interventional case series of 41 eyes of 40 patients with angiographic evidence of PCV, which had PDT with verteporfin. Pre-treatment best-corrected visual acuity (BCVA) was ...

Please provide your email address to receive an email when new articles are posted on . Polypoidal choroidal vasculopathy with multiple polyps did not respond as well to intravitreal ranibizumab as ...

Ranibizumab, in combination with prompt verteporfin photodynamic therapy, is more effective in treating polypoidal choroidal vasculopathy compared with ranibizumab monotherapy, according to a study ...

Interim results of a trial of Roche's Vabysmo have shown its potential to treat patients with polypoidal choroidal vasculopathy, a disorder that leads to vision loss and is a prevalent form of ...

Aflibercept 8 mg administered every 12 or 16 weeks demonstrated comparable improvements in best-corrected visual acuity and central subfield retinal thickness as 2-mg dose every 8 weeks in patients ...

MELBOURNE, Australia, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and ...

In a subgroup analysis of patients with polypoidal choroidal vasculopathy, aflibercept 8 mg achieved similar vision gains to the standard 2-mg dose while allowing a longer treatment interval. An ...